简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

ReWalk Robotics(纳斯达克股票代码:RWLK)股价跌破50天移动平均线0.78美元

2023-03-31 07:32

ReWalk Robotics Ltd. (NASDAQ:RWLK – Get Rating)'s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.78 and traded as low as $0.65. ReWalk Robotics shares last traded at $0.66, with a volume of 95,243 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently commented on RWLK shares. StockNews.com started coverage on shares of ReWalk Robotics in a report on Thursday, March 16th. They issued a "sell" rating for the company. HC Wainwright reissued a "buy" rating and issued a $3.00 price objective on shares of ReWalk Robotics in a research report on Friday, February 24th.

Get ReWalk Robotics alerts:

ReWalk Robotics Price Performance

The stock's 50-day moving average is $0.78 and its two-hundred day moving average is $0.84.

ReWalk Robotics (NASDAQ:RWLK – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The medical device company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). ReWalk Robotics had a negative return on equity of 25.26% and a negative net margin of 355.09%. The firm had revenue of $2.18 million during the quarter, compared to analysts' expectations of $2.10 million. As a group, equities research analysts predict that ReWalk Robotics Ltd. will post -0.33 earnings per share for the current fiscal year.

Insider Transactions at ReWalk Robotics

In related news, major shareholder Global Fund Lp Lind II bought 102,098 shares of ReWalk Robotics stock in a transaction dated Monday, March 6th. The shares were acquired at an average cost of $0.79 per share, with a total value of $80,657.42. Following the completion of the transaction, the insider now owns 4,963,633 shares in the company, valued at approximately $3,921,270.07. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 142,759 shares of company stock valued at $111,730. 0.78% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ReWalk Robotics

A number of institutional investors have recently modified their holdings of RWLK. Renaissance Technologies LLC purchased a new position in shares of ReWalk Robotics during the first quarter worth approximately $35,000. Virtu Financial LLC increased its position in shares of ReWalk Robotics by 249.6% during the fourth quarter. Virtu Financial LLC now owns 47,638 shares of the medical device company's stock worth $36,000 after acquiring an additional 34,013 shares during the period. Finally, Millennium Management LLC increased its position in shares of ReWalk Robotics by 42.9% during the fourth quarter. Millennium Management LLC now owns 139,009 shares of the medical device company's stock worth $106,000 after acquiring an additional 41,753 shares during the period. 4.44% of the stock is owned by hedge funds and other institutional investors.

About ReWalk Robotics

(Get Rating)

ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs.

Read More

  • Get a free copy of the StockNews.com research report on ReWalk Robotics (RWLK)
  • The Squeeze Is On For EVGo, Rally To Follow
  • Is The Bottom In For RH, Or Is This Just A Stopping Point?
  • Dividend King H.B. Fuller Signals Slowing In 2023
  • Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
  • 3 Companies That Just Started Paying Dividends

Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。